Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Spondylitis, Ankylosing 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Pneumonia 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1COVID-19 1Arthritis, Rheumatoid 1

Interventions

BNT162 Vaccine 22019-nCoV Vaccine mRNA-1273 2tocilizumab 1sotrovimab 1heterologous prime boost COVID-19 vaccination 1cilgavimab and tixagevimab drug combination 1Therapeutics 1Specimen Handling 1Sodium Chloride 1Radiotherapy 1Losartan 1Janus Kinase Inhibitors 1Ivermectin 1Interleukin-7 1Hydroxychloroquine 1HuMax-IL8 1Ad26COVS1 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × COVID-19 × tocilizumab × Clear all
NCT04377659 2025-05-28

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
9 enrolled 8 charts

COVID-19, Respiratory Tract Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡